HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Virus Prevention Claims For RhinoSystems’ Naväge Flushed In Nasal Irrigation Advertising Review

Executive Summary

During NAD review, RhinoSystems stated it previously pulled some COVID-19 prevention claims NeilMed challenged and pulled remaining ads after review began. Both RhinoSystems, which markets Naväge brand, and NeilMed, offering a namesake brand, were warned in 2021 by FTC about COVID-19 ad claims.

You may also be interested in...



US FTC Diagnoses Omicron Symptom: More Fraudulent COVID-19 Treatment Claims

Agency says emergence of Omicron variant spurred marketers of products and services from peptide therapy to herbal remedies, and from nasal irrigation to intravenous drips to make false COVID-19 claims. 

Navigating Amazon: E-Commerce Giant Critical For OTC Drug Sales

As Amazon emerges as the leading search engine for information about consumer packaged goods products, OTC drug and other consumer health product firms should establish a presence, even if they expect not to sell much, says BeeKeeper consultancy's Lynn Graham.

California Bill To Age-Restrict Sales Of Diet Pills Further Along Than Other States’ Legislation

CA, MA and NJ legislatures remain in session with bills active proposing regulations similar to NY law effective 22 April requiring retailers, including online, to ask for proof of age when customers buying consumer health products containing ingredients labeled or promoted for weight loss and bodybuilding benefits appear younger than 18.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS153263

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel